Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Airway gene therapy.

Jane C Davies1, Eric W F W Alton

  • 1Department of Gene Therapy, Imperial College London, London SW3 6LR, United Kingdom.

Advances in Genetics
|August 13, 2005
PubMed
Summary
This summary is machine-generated.

Gene therapy for lung diseases like cystic fibrosis (CF) faces barriers but shows promise. Research explores overcoming these challenges with viral and non-viral vectors for improved pulmonary gene delivery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perspective of the European Cystic Fibrosis Society on Improving Global Cystic Fibrosis Care.

Pediatric pulmonology·2026
Same author

Postural Influence on Ventilation Efficiency and Relationship With Oxygen-Enhanced MRI in Cystic Fibrosis.

Pediatric pulmonology·2026
Same author

Maternal, Infant, Reproductive and Child Health in Cystic Fibrosis (MATRIARCH_CF): a prospective, observational study to evaluate pregnancy and parenthood in females with cystic fibrosis and health of the offspring in the CFTR-modulator era.

BMJ open respiratory research·2026
Same author

Using the nose as a factory to secrete proteins into the lungs or circulation.

Molecular therapy. Advances·2026
Same author

Function and Structure Relationships With Inflammation Differ in Two Chronic Suppurative Lung Diseases.

Pediatric pulmonology·2026
Same author

ECFS statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same journal

Shaping mammalian genomes: The regulation and co-option of transposable elements in early development and gametogenesis.

Advances in genetics·2026
Same journal

Transposable elements in aging: From biomarkers to effectors.

Advances in genetics·2026
Same journal

Transposable elements in human cancer: Regulation, activation, and genomic consequences.

Advances in genetics·2026
Same journal

Retrotransposons as both "architects" and "saboteurs" in the nervous system.

Advances in genetics·2026
Same journal

Transposable element analysis in OMICS data.

Advances in genetics·2026
Same journal

The implication of lncRNAs in the regulation of inflammation.

Advances in genetics·2026
See all related articles

Area of Science:

  • Pulmonary Medicine
  • Gene Therapy
  • Respiratory Diseases

Background:

  • The lungs and airways are accessible targets for gene therapy due to genetic pulmonary diseases like cystic fibrosis (CF) and alpha1-antitrypsin (alpha1-AT) deficiency.
  • Current treatments for CF and alpha1-AT deficiency are not curative, making gene therapy a potential therapeutic approach.
  • Gene therapy is being explored for both inherited and acquired lung diseases, including cancer.

Purpose of the Study:

  • To review the barriers to successful gene expression in the airway and alveolar regions.
  • To discuss strategies for overcoming these barriers in pulmonary gene therapy.
  • To highlight progress in clinical trials, particularly with non-viral vectors for various lung diseases.

Main Methods:

  • Review of preclinical and clinical studies involving viral and non-viral vectors for airway gene delivery.

Related Experiment Videos

  • Analysis of challenges in gene expression within the lung parenchyma.
  • Examination of therapeutic strategies for pulmonary diseases.

    • Main Results:

    • Viral vectors have been predominantly used in airway gene therapy studies.
    • Non-viral delivery systems offer advantages for diseases requiring repeated gene therapy applications, such as CF.
    • Significant barriers to gene expression persist in the airway and alveolar regions for both viral and non-viral approaches.

    Conclusions:

    • Despite challenges, gene therapy holds potential for treating a range of pulmonary diseases.
    • Overcoming delivery and expression barriers is crucial for advancing lung gene therapy.
    • Non-viral vectors are emerging as a promising alternative for sustained gene therapy in respiratory conditions.